ASCO President-Elect Julie Vose, MD, MBA

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss the delivery of cancer care in resource-constrained settings such as Rwanda and Haiti, and plans to conduct research in basic tumor biology of patients in these areas.

Leukemia

Lymphoma

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD, on Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

James O. Armitage, MD, of the University of Nebraska Medical Center, and Asher Alban Akmal Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discuss an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).

Skin Cancer

Jedd Wolchok, MD, PhD, and Anthony J. Olszanski, RPh, MD

Jedd Wolchok, MD, PhD, and Anthony J. Olszanski, RPh, MD, on Results From the Checkmate 067 Trial on Nivolumab, Ipilimumab, and Advanced Melanoma

Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).

Lymphoma

Andrew Zelenetz, MD, PhD

Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN

Andrew Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses two important lymphoma trials presented at ASCO and his views on whether their results are indeed practice-changing (Abstract 8504 and LBA8502).

Issues in Oncology

Cost of Care

Charles L. Bennett, MD, PhD, MPP and James O. Armitage, MD

Charles L. Bennett, MD, PhD, MPP, and James O. Armitage, MD, on Biosimilars in Oncology

Charles L. Bennett, MD, PhD, MPP of the University of South Carolina College of Pharmacy, and James O. Armitage, MD, of the University of Nebraska Medical Center, discuss the emerging and future benefits of biosimilars.

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Asher Alban Chanan-Khan, MD, and James O. Armitage, MD, on Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

Jedd Wolchok, MD, PhD, and Anthony J. Olszanski, RPh, MD, on Results From the Checkmate 067 Trial on Nivolumab, Ipilimumab, and Advanced Melanoma

Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN

Charles L. Bennett, MD, PhD, MPP, and James O. Armitage, MD, on Biosimilars in Oncology

EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma

Study Finds Rising Breast Cancer Incidence Across Asian American, Native Hawaiian, and Pacific Islander Groups

Meta-Analysis Highlights Cardiovascular Safety Advantage of Second-Generation BTK Inhibitors

ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases

Tumor Microenvironment Ecotypes May Explain Differences in Multiple Myeloma Outcomes